Donald Trump blasts CEO who raised drug price 5,000 percent: 'He looks like a spoiled brat'


If Martin Shkreli — the pharmaceutical CEO who faced outrage after raising the price of a life-saving medication from $13.50 a pill to $750 — is looking for solace, he won't find any from Donald Trump.
"He looks like a spoiled brat to me," the Republican presidential frontrunner told reporters in South Carolina on Wednesday. "You want to know the truth? He looks like a spoiled brat." In August, Shkreli's Turing Pharmaceuticals acquired the drug Daraprim, which treats taxoplasmosis. A parasitic infection, taxoplasmosis can be fatal for people with weakened immune systems caused by chemotherapy and AIDS. Shkreli said on Monday the price had to go up so the company could "turn a profit," but after backlash from advocacy groups and consumers, he announced Tuesday he changed his mind and would be lowering the cost again over the next few weeks.
That wasn't good enough for Trump, who said Shkreli thought he was "hot stuff" but was actually "zero. He's nothing. He ought to be ashamed of himself." Shkreli was a hedge fund manager before getting into the pharmaceutical business, and Trump has said previously that "hedge fund guys are getting away with murder" and he would do something to change that. "He's a hedge fund guy, who, as you know — the only one that I'm raising taxes on," he said Wednesday. "They are going to be paying up. I thought it was a disgusting thing, what he did. I thought it was a disgrace."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Art Review: Hilma af Klint's What Stands Behind the Flowers
Feature Museum of Modern Art, New York City, through Sept. 27
-
Not just a number: how aging rates vary by country
The explainer Inequality is a key factor
-
'There will be a market incentive to build wind and solar anyway'
Instant Opinion Opinion, comment and editorials of the day
-
Trump administration releases MLK files
Speed Read Newly released documents on the 1968 assassination of the Rev. Dr. Martin Luther King Jr. did not hold any new revelations, King historians said
-
Japan's prime minister feels pressure after election losses
Speed Read Shigeru Ishiba has vowed to remain in office
-
President diagnosed with 'chronic venous insufficiency'
Speed Read The vein disorder has given Trump swollen ankles and visible bruising on his hands
-
'Bawdy' Trump letter supercharges Epstein scandal
Speed Read The Wall Street Journal published details of Trump's alleged birthday letter to Epstein
-
Fed chair Powell in Trump's firing line
Speed Read The president considers removing Federal Reserve Chairman Jerome Powell
-
Trump trashes supporters over Epstein files
speed read The president lashed out on social media following criticism of his administration's Jeffrey Epstein investigation
-
Judge nixes wiping medical debt from credit checks
Speed Read Medical debt can now be included in credit reports
-
Grijalva wins Democratic special primary for Arizona
Speed Read She will go up against Republican nominee Daniel Butierez to fill the US House seat her father held until his death earlier this year